Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

BIOLOGICAL(6)
MIXED(1)
DRUG(1)
second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
1 trial
phase_1
seattle-childrens-hospital
UB_TT170
1 trial
phase_1
seattle-childrens-hospital
Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)
1 trial
phase_1
seattle-childrens-hospital
Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)
1 trial
phase_1
seattle-childrens-hospital
SCRI-E2CAR_EGFRtv1
1 trial
phase_1
seattle-childrens-hospital
second generation 4-1BBζ B7H3-EGFRt-DHFR
1 trial
phase_1
seattle-childrens-hospital
Pembrolizumab
1 trial
phase_1
seattle-childrens-hospital
Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells)
1 trial
phase_1
seattle-childrens-hospital
8 unique interventions3 categories

Analytics

Trial Phases

Phase 13

Trial Status

Other3

Role Distribution

Principal Investigator2
Other Roles1
PI Rate67%

Activity Timeline

Clinical Trials (3)

NCT05312411Phase 1Active Not Recruiting
A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma
Osteosarcoma
PrincipalinvestigatorStart date: 2022-05-20
NCT04483778Phase 1Active Not Recruiting
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
CarcinomaClear Cell SarcomaDesmoplastic Small Round Cell Tumor+14 more
PrincipalinvestigatorStart date: 2020-07-13
NCT02311621Phase 1Active Not Recruiting
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
GanglioneuroblastomaNeuroblastoma
StudychairStart date: 2014-11-25

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Brigitte C Widemann, M.D.

National Cancer Institute (NCI)

Related
19 trials

Shared therapeutic areas:

Sarcoma, EwingMalignant Peripheral Nerve Sheath TumorsSarcoma+4 more
Similarity Score12%

Michael B Gill

Power Life Sciences Inc.

Related
105 trials

Shared therapeutic areas:

NeuroblastomaOsteosarcomaRhabdomyosarcoma+1 more
Similarity Score7%

David S Schrump, M.D.

National Cancer Institute (NCI)

Related
21 trials

Shared therapeutic areas:

SarcomaMelanomaCarcinoma+1 more
Similarity Score7%

E-mail: ClinicalTrials@ ImClone.com

Eli Lilly and Company

Related
22 trials

Shared therapeutic areas:

MelanomaRhabdomyosarcomaSarcoma, Synovial
Similarity Score5%

Mitchell Cairo, MD

New York Medical College

Related
14 trials

Shared therapeutic areas:

NeuroblastomaSarcomaWilms Tumor
Similarity Score5%

James L Gulley, M.D.

National Cancer Institute (NCI)

Related
18 trials

Shared therapeutic areas:

MelanomaCarcinomaSarcoma
Similarity Score5%

Lung-Ji Chang, PhD

Shenzhen Geno-Immune Medical Institute

Related
18 trials

Shared therapeutic areas:

Sarcoma, EwingSarcoma
Similarity Score3%

Stanislaw R. Burzynski, MD, PhD

Burzynski Research Institute

Related
62 trials

Shared therapeutic areas:

NeuroblastomaSarcoma
Similarity Score3%

Javier Martín Broto

Hospital Universitario Fundación Jiménez Díaz

Related
5 trials

Shared therapeutic areas:

SarcomaOsteosarcoma
Similarity Score3%

Xiaoli Lan, PhD

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Related
16 trials

Shared therapeutic areas:

MelanomaSarcoma
Similarity Score3%

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT05312411Phase 1PrincipalInvestigator

A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma

Osteosarcoma
Active Not Recruiting
NCT04483778Phase 1PrincipalInvestigator

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

CarcinomaClear Cell SarcomaDesmoplastic Small Round Cell Tumor+14 more
Active Not Recruiting
NCT02311621Phase 1StudyChair

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

GanglioneuroblastomaNeuroblastoma
Active Not Recruiting

All 3 trials loaded